New Phase II data indicate regimen of Truxima (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma

Media coverage

• Title	New Phase II data indicate regimen of Truxima (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma
  Media name/outlet	FirstWord Pharma
  Country/Territory	United States
  Date	20/6/15
  URL	www.firstwordpharma.com/node/1732861
  Persons	Ki woo Kim